Atosiban

Generic Name
Atosiban
Brand Names
Tractocile, Atosiban SUN
Drug Type
Small Molecule
Chemical Formula
C43H67N11O12S2
CAS Number
90779-69-4
Unique Ingredient Identifier
081D12SI0Z
Background

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in t...

Indication

Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with:

Associated Conditions
Premature Births
Associated Therapies
-
Clinical Trials
Related News

Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)

Not Applicable
Completed
Conditions
Premature Birth
Cervical Cerclage
Interventions
Drug: Atosiban
Drug: Normal saline
First Posted Date
2024-08-05
Last Posted Date
2024-08-06
Lead Sponsor
Children's Hospital of Chongqing Medical University
Target Recruit Count
334
Registration Number
NCT06537778
Locations
🇨🇳

Women and Children's Hospital of Chongqing Medical University, Chongqing, Chognqing, China

🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth

Phase 4
Completed
Conditions
Preterm Birth
Interventions
Drug: Atosiban
First Posted Date
2023-01-23
Last Posted Date
2024-07-25
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
760
Registration Number
NCT05693688
Locations
🇳🇱

Amsterdam University Medical Centres, location AMC, Amsterdam, Noord-Holland, Netherlands

The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain

Phase 2
Conditions
Endometriosis
Interventions
Drug: Atosiban
First Posted Date
2022-05-19
Last Posted Date
2022-05-19
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
10
Registration Number
NCT05382143
Locations
🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline

First Posted Date
2020-07-13
Last Posted Date
2022-06-06
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
25
Registration Number
NCT04468568
Locations
🇧🇷

Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer

Not Applicable
Conditions
Infertility, Female
Interventions
Drug: Atosiban
First Posted Date
2019-04-05
Last Posted Date
2020-12-16
Lead Sponsor
Bezmialem Vakif University
Target Recruit Count
250
Registration Number
NCT03904745
Locations
🇹🇷

Yeditepe University, Istanbul, Turkey

🇹🇷

Bezmialem University, Istanbul, Turkey

Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

Not Applicable
Completed
Conditions
Premature Birth
Interventions
Drug: Atosiban
First Posted Date
2018-06-26
Last Posted Date
2019-06-14
Lead Sponsor
Polish Mother Memorial Hospital Research Institute
Target Recruit Count
64
Registration Number
NCT03570294
Locations
🇵🇱

Department of Obstetrics, Perinatology and Gynecology, Polish Mother's Memorial Hospital-Research Institute, Łódź, Poland

PoC Study of OBE022 in Threatened Preterm Labour

First Posted Date
2017-12-11
Last Posted Date
2021-06-07
Lead Sponsor
ObsEva SA
Target Recruit Count
115
Registration Number
NCT03369262
Locations
🇮🇱

Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women, Petah tikva, Israel

🇮🇱

Rambam Medical Center, Maternal Fetal Unit, Haifa, Israel

🇨🇿

Gynekologicko-porodnická klinika Fakultní nemocnice Brno, Brno, Czechia

and more 15 locations

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

First Posted Date
2016-09-08
Last Posted Date
2016-09-08
Lead Sponsor
Shanghai First Maternity and Infant Hospital
Target Recruit Count
200
Registration Number
NCT02893722

Tocolytic Therapy for Preterm Labor in Multiple Gestation

First Posted Date
2016-04-01
Last Posted Date
2016-04-01
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
140
Registration Number
NCT02725736

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

First Posted Date
2014-11-17
Last Posted Date
2020-07-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
98
Registration Number
NCT02292784
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy